Weekend Reading | How Johnson & Johnson Orthopedics' Empire Dream Was Shattered?
The opportunity for the pharmaceutical industry to explode must be hidden in the unmet clinical needs, which are the directions that pharmaceutical companies need to continue to cultivate.
Small, Mid-size Biotechs Could See M&A Action in H2 - PwC
"Weight-loss miracle drug" has new benefits. Research shows that GLP-1 drugs may help reduce the risk of cancer.
The Centers for Disease Control and Prevention (CDC) in the USA states that obesity increases the risk of developing 13 cancers, while the latest research examines the health records of diabetes patients and finds that some diabetes treatments may help prevent obesity-related cancers.
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
What's Going On With Eli Lilly Shares Friday?
Eli Lilly and Co. (NYSE:LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.What's Happening: Morgan Stanley has maintained its Overweight rating on Eli Lill
Shares of Lilly and Novo Nordisk Are Trading Higher Following a Study Showing Patients Taking GLP-1 Treatments Have a Reduced Risk of Developing Obesity-related Cancers.
Shares of Lilly and Novo Nordisk Are Trading Higher Following a Study Showing Patients Taking GLP-1 Treatments Have a Reduced Risk of Developing Obesity-related Cancers.
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and othe
Merck & Co Unusual Options Activity
Financial giants have made a conspicuous bearish move on Merck & Co. Our analysis of options history for Merck & Co (NYSE:MRK) revealed 8 unusual trades.Delving into the details, we found 12% of trade
Executive Reshuffles: NIO, Pfizer and Spirit Airlines in Focus
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.'s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees an
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
'FDA to Evaluate Potential Risk of Neural Tube Birth Defects With HIV Medicine Dolutegravir (Juluca, Tivicay, Triumeq)' - FDA
'FDA to Evaluate Potential Risk of Neural Tube Birth Defects With HIV Medicine Dolutegravir (Juluca, Tivicay, Triumeq)' - FDA
What's Going On With Johnson and Johnson Shares Friday?
Johnson and Johnson (NYSE:JNJ) shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clinical trials and authorization from Health Canada for
Smart Money Is Betting Big In LLY Options
High-rolling investors have positioned themselves bearish on Eli Lilly and Co (NYSE:LLY), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga
Morgan Stanley Maintains Overweight on Eli Lilly and Co, Maintains $1023 Price Target
Morgan Stanley analyst Terence Flynn maintains Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $1023 price target.
Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/05/2024 14.02% Morgan Stanley $1023 → $1023 Maintains Overweight 07/03/2024 11.57% BMO Capital $1001 →
Pfizer Names Former State Street CEO Taraporevala to Board
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
On Thursday, Roche Holdings AG (OTC:RHHBY) said that the Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as first-line
Reported Thursday, Calliditas Therapeutics And Viatris Initiate Phase III Clinical Trial Of Nefecon For IgA Nephropathy In Japan
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated
Here's How Much $100 Invested In Eli Lilly and Co 15 Years Ago Would Be Worth Today
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 11.54% on an annualized basis producing an average annual return of 24.56%. Currently, Eli Lilly and Co has a market c